Napredna pretraga

Pregled bibliografske jedinice broj: 606024

Oncogenic HPV and cervical cancer


Grce, Magdalena
Oncogenic HPV and cervical cancer // Abstract Book of the 3rd International Congress of Kosovo and Albanian Oncologist, Prishtina, Kosovo, 02.-03.11.2012. / Sllamniku, Besim ; Manxhuka-Kerliu, Suzana (ur.).
Prishtina, Kosovo: Kosovo Association of Oncology, 2012. str. 24-24 (plenarno, nije recenziran, pp prezentacija, znanstveni)


Naslov
Oncogenic HPV and cervical cancer

Autori
Grce, Magdalena

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, pp prezentacija, znanstveni

Izvornik
Abstract Book of the 3rd International Congress of Kosovo and Albanian Oncologist, Prishtina, Kosovo, 02.-03.11.2012. / Sllamniku, Besim ; Manxhuka-Kerliu, Suzana - Prishtina, Kosovo : Kosovo Association of Oncology, 2012, 24-24

Skup
3rd International Congress of Kosovo and Albanian Oncologist

Mjesto i datum
Prishtina, Kosovo, 02.-03.11.2012

Vrsta sudjelovanja
Plenarno

Vrsta recenzije
Nije recenziran

Ključne riječi
HPV; cervical cancer

Sažetak
Human papillomavirus (HPV) is one of the most common sexually transmitted viruses. Although the majority of HPV infections are transient, some infections persist and progress to cervical pre-cancer/cancer. A subset of 15 HPV types, including HPV types 16 and 18, are associated >99% of cervical cancers and are considered carcinogenic. The carcinogenic pathway often includes the integration of the HPV DNA into the host genome with increased expression of the HPV E6 and E7 genes. The E6 and E7 proteins bind and inactivate the p53 and pRB tumour-suppressor proteins, respectively, and lead to cell proliferation. Both, E6 and E7 expression are necessary for the onset and progression of cervical cancer. Based on this knowledge, HPV-based strategies have been investigated to better control cervical cancer rates. In particular, HPV DNA testing has been clearly shown to be very useful for the triage of ASCUS cytology, and for the follow-up of women treated for cervical intraepithelial neoplasia. HPV DNA testing has also been evaluated as a primary screening test in large, randomised, controlled trials where it has been demonstrated to be more sensitive and objective than the Pap test, although a little less specific. In addition to HPV DNA testing, other HPV-associated biomarkers are being evaluated in clinical trials, notably the expression of E6 and E7 mRNA, and the expression of cellular protein p16INK4a. Finally, HPV vaccines have been developed and shown to be highly effective in the prevention of both HPV infection with HPV types 16 and 18, together with lower levels of protection against one or more closely related types, and against the disease caused by these types. The performance data for these HPV-based technologies, together with their implications for cervical cancer prevention programmes will be discussed.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Projekt / tema
098-0982464-2510 - Promijenjeno stanje DNA-metilacije u HPV-povezanim oštećenjima (Magdalena Grce, )

Ustanove
Institut "Ruđer Bošković", Zagreb

Autor s matičnim brojem:
Magdalena Grce, (138731)